Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.

scientific article published on 30 March 2011

Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/CLPT.2011.33
P698PubMed publication ID21451509
P5875ResearchGate publication ID50936922

P2093author name stringP Zhang
Y Wang
T J Schall
D A Johnson
L C Seitz
Y Zeng
S Miao
D J Dairaghi
J C Jaen
P Bekker
A M Pennell
J P Powers
L S Ertl
P2860cites workThe many roles of chemokines and chemokine receptors in inflammationQ29618880
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantationQ33446708
Microbes in gastrointestinal health and diseaseQ33943525
Maraviroc for previously treated patients with R5 HIV-1 infectionQ34806062
Chemokines and chemokine receptors in rheumatoid arthritisQ35031896
Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritisQ35553008
Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritisQ35636896
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.Q36141697
Chemokines and leukocyte trafficking in rheumatoid arthritisQ36354494
The role of chemokines in rheumatoid arthritis and osteoarthritisQ36360715
Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptorQ36401511
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissuesQ36742483
Chemokines and their receptors: drug targets in immunity and inflammationQ36947059
Chemokine receptor antagonists: Part 1.Q37481238
Chemokine receptor antagonists: part 2.Q37481304
Anti-chemokine small molecule drugs: a promising future?Q37683772
CCR1 antagonists: what have we learned from clinical trialsQ37763962
CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblastsQ38334431
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseQ39675706
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritisQ39763545
Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trialQ39850979
Impact of digital ulcers on disability and health-related quality of life in systemic sclerosisQ39874145
Proteolytic activation of alternative CCR1 ligands in inflammationQ40419745
CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseasesQ42605598
Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexateQ42956746
Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonistQ43248464
A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbitQ44223900
Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005.Q44914209
Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects.Q46323881
Chemokines and T lymphocytes: more than an attractionQ47713299
Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715.Q51465120
Blockade of chemokine signaling in patients with multiple sclerosisQ57623592
Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activityQ73092605
Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarkerQ81517383
CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) miceQ84741014
MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept studyQ84966679
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectpharmacokineticsQ323936
pharmacodynamicsQ725307
human subject research projectQ1331083
P304page(s)726-734
P577publication date2011-03-30
P1433published inClinical Pharmacology & TherapeuticsQ1101529
P1476titlePharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.
P478volume89

Reverse relations

cites work (P2860)
Q38936733A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy
Q37524080C5a receptor (CD88) blockade protects against MPO-ANCA GN
Q27308841CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages
Q39862548CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer.
Q36177928CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease
Q33816616CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice
Q36170691Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study
Q91199065Chemokines in rheumatic diseases: pathogenic role and therapeutic implications
Q48268499Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial.
Q53309302European League against rheumatism - selected presentation and poster a highlights June 11th to 13th 2013.
Q38978556Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays
Q57175297Inhibition of CCL3 abrogated precursor cell fusion and bone erosions in human osteoclast cultures and murine collagen-induced arthritis
Q37432097International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors
Q46441158Overcoming hurdles in developing successful drugs targeting chemokine receptors
Q57787493Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2
Q90642824Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis
Q38647749Successes and failures of chemokine-pathway targeting in rheumatoid arthritis
Q38148785Targeting CCL5 in inflammation
Q39158831The Multifunctional Role of the Chemokine System in Arthritogenic Processes
Q37948866Therapeutic potential of CCR1 antagonists for multiple myeloma.
Q34076041Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation
Q28742993Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis

Search more.